Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating
CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 4th
CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings
CorMedix's acquisition of Melinta Therapeutics diversifies its portfolio, boosting 2025 revenue guidance to at least $375M and reducing single-product risk. DefenCath remains the primary revenue driver, but pipeline and Melinta's hospital-focused drugs provide additional growth and risk mitigation. CorMedix is rated a Strong Buy, with a base-case fair value of $27.8, offering ~147% upside from current levels.
Earnings Estimates Rising for CorMedix (CRMD): Will It Gain?
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
CorMedix: The Undervalued Breakthrough
CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.
